Head-to-Head

Halozyme Therapeutics, Inc. vs. Inhibikase Therapeutics, Inc. Common Stock

HALO

Halozyme Therapeutics, Inc.

$112.45 +2.53%

VS IKT

Inhibikase Therapeutics, Inc. Common Stock

$2.23 -3.26%

Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.

Size & Scale

HALOIKT
Market Cap $12.76 billion $320.93 million
Revenue (TTM) $1.66 billion $3.72 million
Net Income (TTM) $413.60 million $-60,637,002

HALO leads on 3 of 3 size & scale factors.

Valuation

HALOIKT
P/E Ratio 32.78 —
Price / Book 88.91 2.09
Price / Sales 7.67 86.39

HALO and IKT split the valuation factors evenly.

Profitability

HALOIKT
Net Margin 24.86% -1632.18%
Return on Equity 288.13% -39.55%

HALO leads on 2 of 2 profitability factors.

Risk & Sentiment

HALOIKT
Short Interest 9.79% 0.02%

IKT leads on 1 of 1 risk & sentiment factors.

Dig deeper: HALO overview, HALO financials, IKT overview, IKT financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.